Yearly Archives: "2019"

2019 CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis
This guideline was developed by a group of multiple sclerosis (MS) specialists, convened by the Consortium of Multiple Sclerosis Centers [...]
FDA approves first generics for common multiple sclerosis drug
The FDA has approved 3 applications for generics of fingolimod (Gilenya, Novartis). These are the first generics of the drug, which treats [...]
Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with [...]
NeurologyLiveâ„¢ adds CMSC to its Strategic Alliance Partnership program
CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLiveâ„¢, a multimedia platform dedicated to providing health care professionals treating [...]
In Memoriam: Alan Mandel
Our dear friend and colleague Alan Mandel passed away early Monday morning, November 4, 2019. He fought hard in his battle against PML and [...]
Comprehensive Palliative Care in MS: CMSC Consensus Statement and Proposed Guidelines
Several organizations have expressed interest and published guidelines or consensus statements emphasizing the need for palliative care for [...]
Kessler scientists receive grant to study exercise benefits in multiple sclerosis
East Hanover, NJ. October 7, 2019. With a grant from the Consortium of Multiple Sclerosis Centers, John DeLuca, PhD, Helen Genova, PhD, of [...]
EMD Serono initiates pivotal Phase III program for investigational Evobrutinib in RMS
ROCKLAND, Mass., Sept. 10, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. [...]
Genentech presents new six-year Ocrevus (Ocrelizumab) data
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM